Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT

NCT00761241 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: Gemcitabine, Docetaxel, 5FU, Oxaliplatin
BIOLOGICAL: Alpha-interferon
RADIATION: Abdominal/pelvic radiation therapy
PROCEDURE: Pancreaticoduodenectomy

Sponsor

Benaroya Research Institute

Collaborators

[object Object]